Tag Archives: secondary care
December 2020 Br J Cardiol 2020;27(suppl 2):S2–S16 doi:10.5837/bjc2020.s05
Adapting cardiovascular disease care to the ‘new norm’ of the COVID-19 era: same standard, different delivery
Martin R Cowie, Matthew Fay, Jo Jerrome, Abhishek Joshi, Jim Moore, Helen Williams
Introduction to the steering committee From left to right: Professor Martin Cowie, Dr Matthew Fay, Ms Jo Jerrome,Dr Abhishek Joshi, Dr Jim Moore, Ms Helen Williams Conflicts of interest The steering committe received speaking and consultation fees from Bayer plc. MRC provides consultancy advice to Abbott, AstraZeneca, Bayer, Boston Scientific, Medtronic, Novartis, Roche Diagnostics and Servier. MF has received speaker honoraria, conference sponsorship, unrestricted educational grants, and/or attended meetings sponsored by AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Medtronic, Novartis, Pfizer, Roche, Sanofi-Aventis, and S
May 2007 Br J Cardiol 2007;14:125-126
The new SIGN guidance on CHD and its implications for secondary care
Kevin Jennings, Lewis Ritchie
No content available
April 2002 Br J Cardiol 2002;9:
The evidence for secondary prevention and cardiac rehabilitation in hospitals
Jane Flint
No content available
For healthcare professionals only
